161 related articles for article (PubMed ID: 19212214)
41. Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management.
Brière JB
Semin Thromb Hemost; 2006 Apr; 32(3):208-18. PubMed ID: 16673275
[TBL] [Abstract][Full Text] [Related]
42. [Novel method in diagnosis of chronic myeloproliferative disorders--detection of JAK2 mutation].
Rajnai H; Bödör C; Reiniger L; Timár B; Csernus B; Szepesi A; Csomor J; Matolcsy A
Orv Hetil; 2006 Nov; 147(45):2175-9. PubMed ID: 17402211
[TBL] [Abstract][Full Text] [Related]
43. Chronic lymphocytic leukemia developing in a patient with Janus kinase 2 V617F mutation positive myeloproliferative neoplasm.
Eskazan AE; Salihoglu A; Diz-Kucukkaya R; Hancer VS; Soysal T
Ann Hematol; 2012 Feb; 91(2):305-6. PubMed ID: 21584669
[No Abstract] [Full Text] [Related]
44. Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder.
Bourke MG; Martin ST; O'Dwyer M; Hanaghan J; Bennani F; Barry MK
Ir J Med Sci; 2012 Jun; 181(2):285-7. PubMed ID: 19693645
[TBL] [Abstract][Full Text] [Related]
45. [Portal vein and hepatic vein thrombosis in occult myeloproliferative syndrome. Progression of thrombosis under heparin therapy].
Frey HR; Suter B
Schweiz Med Wochenschr; 1996 Aug; 126(34):1437-41. PubMed ID: 8848706
[TBL] [Abstract][Full Text] [Related]
46. [Budd-Chiari syndrome and splanchnic vein thrombosis: masked myeloproliferative neoplasms and JAK2V617F].
Fama A; Rago A; Gioiosa F; Marzano C; Latagliata R; Mammì C; Laganà C; D'Elia GM; Bizzoni L; Trasarti S; Ferretti A; Breccia M; Riggio O; Tafuri A
Clin Ter; 2010; 161(2):169-71. PubMed ID: 20499034
[TBL] [Abstract][Full Text] [Related]
47. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders.
Rumi E; Passamonti F; Pietra D; Della Porta MG; Arcaini L; Boggi S; Elena C; Boveri E; Pascutto C; Lazzarino M; Cazzola M
Cancer; 2006 Nov; 107(9):2206-11. PubMed ID: 16998940
[TBL] [Abstract][Full Text] [Related]
48. Detection of the JAK2 V617F missense mutation by high resolution melting analysis and its validation.
Er TK; Lin SF; Chang JG; Hsieh LL; Lin SK; Wang LH; Lin CW; Chang CS; Liu TC
Clin Chim Acta; 2009 Oct; 408(1-2):39-44. PubMed ID: 19595684
[TBL] [Abstract][Full Text] [Related]
49. Occult myeloproliferative neoplasms: not so occult any more.
Karam D; Iyer V; Agrawal B
BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28559287
[TBL] [Abstract][Full Text] [Related]
50. [JAK2 mutation and thrombosis - recommendations for screening].
Linnemann B; Lindhoff-Last E
Dtsch Med Wochenschr; 2011 Dec; 136(48):2454-7. PubMed ID: 22109574
[No Abstract] [Full Text] [Related]
51. Occurrence of the JAK2 V617F mutation in the Budd-Chiari syndrome.
Colaizzo D; Amitrano L; Tiscia GL; Iannaccone L; Gallone A; Grandone E; Guardascione MA; Margaglione M
Blood Coagul Fibrinolysis; 2008 Jul; 19(5):459-62. PubMed ID: 18600100
[TBL] [Abstract][Full Text] [Related]
52. The "pseudo-cholangiocarcinoma sign" in patients with cavernous transformation of the portal vein and its effect on the serum alkaline phosphatase and bilirubin levels.
Bayraktar Y; Balkanci F; Ozenc A; Arslan S; Koseoglu T; Ozdemir A; Uzunalimoglu B; Telatar H; Gurakar A; Van Thiel DH
Am J Gastroenterol; 1995 Nov; 90(11):2015-9. PubMed ID: 7485013
[TBL] [Abstract][Full Text] [Related]
53. The JAK2 V617F mutation in patients with cerebral venous thrombosis: a rebuttal.
De Stefano V; Rossi E; Za T; Chiusolo P; Leone G
Thromb Haemost; 2008 Jun; 99(6):1121. PubMed ID: 18521519
[No Abstract] [Full Text] [Related]
54. Rapid real-time PCR assay for detection of MPL W515L mutation in patients with chronic myeloproliferative disorders.
Ghaderi M; Strömberg O; Porwit A
Int J Lab Hematol; 2010 Feb; 32(1 Pt 2):122-6. PubMed ID: 19016916
[TBL] [Abstract][Full Text] [Related]
55. [Essential thrombocythemia. Contribution of the V617F JAK2 mutation to the pathophysiology, diagnosis and outcome].
Brière J
Bull Acad Natl Med; 2007 Mar; 191(3):535-48. PubMed ID: 18072652
[TBL] [Abstract][Full Text] [Related]
56. [The investigation of JAK2 V617F point mutation in myeloproliferative disorders by allele-specific polymerase chain reaction in combination with sequence analysis].
Zhang SJ; Li WD; Song JH; Xu W; Qiu HX; Li JY
Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(30):2109-12. PubMed ID: 17988529
[TBL] [Abstract][Full Text] [Related]
57. A simple, rapid, and sensitive method for the detection of the JAK2 V617F mutation.
Tan AY; Westerman DA; Dobrovic A
Am J Clin Pathol; 2007 Jun; 127(6):977-81. PubMed ID: 17509995
[TBL] [Abstract][Full Text] [Related]
58. Portal vein thrombosis as the presenting manifestation of JAK2 positive myeloproliferative neoplasm.
Jeon WJ; Mehta A; Hudson J; Castillo DR; Wang J; Nguyen A; Akhtari M
Am J Med Sci; 2023 May; 365(5):457-461. PubMed ID: 36632865
[TBL] [Abstract][Full Text] [Related]
59. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
Mercier F; Monczak Y; François M; Prchal J; Galipeau J
Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
[TBL] [Abstract][Full Text] [Related]
60. Is the JAK2 V617F mutation a hallmark for different forms of thrombosis?
Zerjavic K; Zagradisnik B; Stangler Herodez S; Lokar L; Glaser Krasevac M; Kokalj Vokac N
Acta Haematol; 2010; 124(1):49-56. PubMed ID: 20616539
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]